Pharmaceutical industry
Investor Broadcast Network has announced a significant expansion of its webcasting services for investor communication conferences. By leveraging the power of the internet, the network now allows public companies to broadcast their investor communication conference calls, making it possible for investors to access the information in real-time. This development is
Pharmaceutical industry
Medarex, Inc., a biopharmaceutical company, has agreed to produce fully human antibodies for several disease targets under a new collaboration with Eli Lilly and Company. This partnership will accelerate the introduction of antibody candidates into clinical investigation for important disease targets, leveraging Medarex's proprietary technologies and expertise. The
Drugs
Researchers at The Immune Response Corp. in California may have developed the ideal candidate HIV-1 vaccine for testing in both primates and humans. The vaccine combines a whole-killed gp120-depleted HIV antigen with immunostimulatory sequences, which stimulated both CD4 and CD8 immune responses in a Lewis rat model. The study suggests
Drugs
Standard & Poor's will be making several changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 Indices on November 1, 2000. Key changes include the addition of NiSource Inc. to the S&P 500 Index, Dycom Industries to
Drugs
CEL-SCI Corporation, a developer of Cancer Immuno-Therapy Products, has announced that it has sent a letter to Dr. Bobba Venkatadri, CEO of Molecular Biosystems, Inc. (MBI), stating its intention to acquire MBI at a price of $0.76 per share. This offer represents a significant premium over the price offered
Drugs
InvestmentHouse.com, a leading Internet-based stock information site, is providing stock split notifications via email to its subscribers, offering a unique service that helps investors stay informed about upcoming stock splits. The company's Stock Split Report, which forecasts stock splits before they are announced, is also available on
Drugs
Genmab A/S, a biotechnology company specializing in developing fully human antibodies to treat various life-threatening and debilitating diseases, has announced plans to seek listings on the Copenhagen and Frankfurt stock exchanges in October 2000. The company, founded in February 1999 through a joint effort between Medarex and Danish investors,
Drugs
Corixa Corporation and Medicis Pharmaceutical Corporation have entered into a multi-year development, commercialization, and license agreement for Corixa's novel psoriasis immunotherapeutic product, PVAC. Under the agreement, Medicis will have exclusive rights to PVAC treatment in the United States and Canada, while Corixa will be responsible for development and
Drugs
Chiron Corporation, a leading biotechnology company, has entered into a definitive agreement to acquire PathoGenesis Corporation for approximately $700 million. The acquisition positions Chiron as a global player in the treatment and prevention of infectious diseases and cancer. The combined company will have a substantially expanded therapeutic focus in infectious
Drugs
The Nasdaq Biotechnology Index saw a significant surge of over 6% on Friday, driven by the performance of top biotech companies such as Sepracor, Transkaryotic Therapeutics, and Ribozyme Pharmaceuticals. These companies were among the 15 presenting at the Boston Biotechnology Forum, held at the Seaport Hotel and online at informedinvestors.
Drugs
Genta Incorporated, a biopharmaceutical company specializing in anticancer therapy, has partnered with Molecular Biosystems Inc. to license a comprehensive portfolio of patents and technology related to antisense therapeutic and diagnostic applications. The agreement grants Genta exclusive and non-exclusive rights to the technology, allowing the company to expand its intellectual property
Drugs
Nanjing Huaxin Biotech Co., Ltd. has acquired co-development rights to a Pichia yeast culture system for the production of TPO (thrombopoietin) from Kelong Industrial Co., Ltd, a Chinese company. Dragon Pharmaceuticals, which holds a 75% equity interest in Nanjing Huaxin, has announced the acquisition, highlighting the potential for a higher
